1Kameda N, Okuya S, Oka Y. Rosiglitazone (BRL-49653). Nippon Rinsho, 2000, 58 (2): 401-404.
2Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol, 1999, 48 (3): 424-432.
3Wolffenhuttel BH, Gomis R, Squatrito S, et al. Addition of low dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med, 2000, 17 (1) : 40-47.
4Practical Living. Investigational drug shown to lower blood glucose. Diabetes Forecast, 1999, 52 (2): 33-36.
5Adis International Limited. Rosiglitazone: a promising new thiazoledinedione. Drug Ther Bull, 1999, 14 (6): 1-5.
6潘孝仁，Diabretes Care，1993年，16卷，150页
7胡英华，中华内科杂志，1993年，32卷，173页
8团体著者，中华内科杂志，1981年，20卷，678页
9Balkau B, Charles MA. Comments on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance. Diabet Med, 1999,16:442-443.
10Reusch JE. Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome. Am J Cardiol,2002,90:19G-26G.
